Events¶
Overview
| Date | Event | Status |
|---|---|---|
| 24 June 2026 | GUF Meeting - Paris, France | Planned |
| 13 July 2026 | Community Meeting (virtual) | Scheduled |
| 15-18 November 2026 | PHUSE EU Connect - Glasgow, Scotland | Planned |
GUF Meeting - Paris, France¶
(24 June 2026, Paris, France)
Join us at the French CDISC User Group meeting in Paris. Nicolas will be available to connect and there will be likely a presentation on CDISC 360i which is highly related to OpenStudyBuilder. Additional information will be shared later.
Community Meeting (virtual)¶
(13 July 2026, virtual event, 15:00-16:00 CEST)
Join us at the OpenStudyBuilder community meeting! Don't miss out on the opportunity to ask any questions to us! We can demonstrate various functionality and provide insightful answers. We can discuss on a wide range of subjects.
You can register for the event here.
PHUSE EU Connect¶
(15-18 November 2026 - Glasgow, Scotland)
We will join the PHUSE EU Connect in Glasgow. Please come by, talk to us and also checkout our presentation on collaboration challenges.
Additional event information and registration is available here.
Beyond Code: Collaboration Challenges in Pharma Open Source
(by Mikkel Traun, Novo Nordisk and Katja Glaß, Consultant)
"Open-source adoption in the pharmaceutical industry continues to grow, yet sustainable contributions and long-term collaboration remain significant challenges. Compared to other industries, contribution models in pharma are often limited by complexity, compliance expectations, fragmented ownership, and uncertainty around governance and maintenance responsibilities.
This presentation explores key challenges surrounding open-source collaboration in clinical research using OpenStudyBuilder as a practical example. It outlines the considerations, experiences, and developments that led to the creation of a collaborative alliance model designed to strengthen industry alignment, co-development, and long-term sustainability. The session highlights how the alliance evolved, its current state, and its future direction in advancing OpenStudyBuilder toward enabling a truly connected digital data flow for the pharmaceutical industry."